2kp8
From Proteopedia
(Difference between revisions)
| (8 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{Seed}} | ||
| - | [[Image:2kp8.jpg|left|200px]] | ||
| - | < | + | ==Ligand bound to a model peptide that mimics the open fusogenic form== |
| - | + | <StructureSection load='2kp8' size='340' side='right'caption='[[2kp8]]' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[2kp8]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2KP8 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2KP8 FirstGlance]. <br> | |
| - | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr> | |
| - | --> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=XIG:5-{[(4-METHOXYBIPHENYL-4-YL)METHYL][(1S)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL]CARBAMOYL}BENZENE-1,2,4-TRICARBOXYLIC+ACID'>XIG</scene></td></tr> |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2kp8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2kp8 OCA], [https://pdbe.org/2kp8 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2kp8 RCSB], [https://www.ebi.ac.uk/pdbsum/2kp8 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2kp8 ProSAT]</span></td></tr> | |
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The ectodomain of HIV-1 gp41 mediates the fusion of viral and host cellular membranes. The peptide-based drug Enfuvirtide(1) is precedent that antagonists of this fusion activity may act as anti HIV-agents. Here, NMR screening was used to discover non-peptide leads against this target and resulted in the discovery of a new benzamide 1 series. This series is non-peptide, low molecular weight, and analogs have activity in a cell fusion assay with EC50 values ranging 3-41microM. Structural work on the gp41/benzamide 1 complex was determined by NMR spectroscopy using a designed model peptide system that mimics an open pocket of the fusogenic form of the protein. | ||
| - | + | Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.,Stewart KD, Huth JR, Ng TI, McDaniel K, Hutchinson RN, Stoll VS, Mendoza RR, Matayoshi ED, Carrick R, Mo H, Severin J, Walter K, Richardson PL, Barrett LW, Meadows R, Anderson S, Kohlbrenner W, Maring C, Kempf DJ, Molla A, Olejniczak ET Bioorg Med Chem Lett. 2010 Jan 15;20(2):612-7. Epub 2009 Nov 20. PMID:20004576<ref>PMID:20004576</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | <div class="pdbe-citations 2kp8" style="background-color:#fffaf0;"></div> | |
| - | + | == References == | |
| - | + | <references/> | |
| - | + | __TOC__ | |
| - | + | </StructureSection> | |
| - | == | + | |
| - | + | ||
| - | + | ||
| - | == | + | |
| - | < | + | |
[[Category: Escherichia coli]] | [[Category: Escherichia coli]] | ||
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: | + | [[Category: Olejniczak ET]] |
| - | + | ||
| - | + | ||
Current revision
Ligand bound to a model peptide that mimics the open fusogenic form
| |||||||||||
